<p>CIBC 私人财富集团有限公司在最近向证券交易委员会的披露中表示，在第四季度将其在 Bio-Rad Laboratories, Inc.（纽约证券交易所代码：BIO - 免费报告）的股份减少了 2.9%。该公司在本季度出售了 1,243 股后，持有 42,106 股该医疗研究公司的股票。根据其最近向证券交易委员会的备案，CIBC 私人财富集团有限公司持有 Bio-Rad Laboratories 的 0.15% 股份，价值 14,500,000 美元。</p>
<p>获取 <strong>Bio-Rad Laboratories</strong> 的提醒：</p>
<ul>
<li>标普 500 震荡：新进入者推动市场动能</li>
</ul>
<p>其他大型投资者最近也对该公司的持仓进行了调整。Venturi 财富管理有限公司在第四季度将其在 Bio-Rad Laboratories 的股份增加了 2,175.0%。Venturi 财富管理有限公司现在拥有 91 股该医疗研究公司的股票，价值 30,000 美元，此前在上个季度又购买了 87 股。Picton Mahoney 资产管理在第四季度将其在 Bio-Rad Laboratories 的股份增加了 55.6%。Picton Mahoney 资产管理现在拥有 98 股该医疗研究公司的股票，价值 32,000 美元，此前在上个季度又收购了 35 股。Asset Planning Inc 在第四季度收购了 Bio-Rad Laboratories 的新股份，价值约 33,000 美元。UMB 银行在第四季度将其在 Bio-Rad Laboratories 的持股增加了 41.6%。UMB 银行现在拥有 109 股该医疗研究公司的股票，价值 36,000 美元，此前在上个季度又购买了 32 股。最后，Cape Investment Advisory Inc 在第四季度购买了 Bio-Rad Laboratories 的新股份，价值约 38,000 美元。目前，65.24% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>分析师升级和降级</h2>
<p>一些股票研究分析师最近对该股票发布了报告。加拿大皇家银行在 1 月 14 日的报告中重申了 “跑赢大盘” 的评级，并对 Bio-Rad Laboratories 的股票设定了 481.00 美元的目标价。富国银行将 Bio-Rad Laboratories 的目标价从 360.00 美元下调至 345.00 美元，并在 2 月 12 日的报告中对该股票设定了 “持平” 的评级。最后，StockNews.com 在 2 月 17 日的报告中将 Bio-Rad Laboratories 的评级从 “买入” 下调至 “持有”。三位研究分析师对该股票给予了持有评级，三位分析师则给予了买入评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，共识目标价为 395.20 美元。</p>
<ul>
<li>现在值得购买的前三大医疗设备股票</li>
</ul>
<p><strong>阅读我们关于 BIO 的最新研究报告</strong></p>
<h2>Bio-Rad Laboratories 股票上涨 0.5%</h2>
<p>纽约证券交易所 BIO 的股票在周二开盘价为 244.29 美元。该公司的债务与股本比率为 0.18，速动比率为 4.85，流动比率为 6.48。Bio-Rad Laboratories, Inc.的 1 年最低价为 235.84 美元，1 年最高价为 387.99 美元。该股票的 50 日简单移动平均线为 291.56 美元，200 日简单移动平均线为 321.95 美元。该公司的市值为 68.4 亿美元，市盈率为-3.76，贝塔值为 0.98。</p>
<p>Bio-Rad Laboratories（纽约证券交易所代码：BIO - 获取免费报告）最后一次公布财报是在 2 月 13 日，医疗研究公司报告本季度每股收益（EPS）为 2.90 美元，超出分析师的共识预期 2.86 美元，超出幅度为 0.04 美元。Bio-Rad Laboratories 的股本回报率为 3.90%，净利润率为-71.86%。整体来看，股票分析师预计 Bio-Rad Laboratories, Inc.在当前财年将发布 10.81 美元的每股收益。</p>
<h2>关于 Bio-Rad Laboratories</h2>
<p>（免费报告）</p>
<p>Bio-Rad Laboratories, Inc.在美国、欧洲、亚洲、加拿大和拉丁美洲制造和分销生命科学研究和临床诊断产品。它通过两个部门运营，分别是生命科学和临床诊断。该公司开发、制造和销售仪器、系统、试剂和耗材，以分离、纯化、表征和定量生物材料，如细胞、蛋白质和核酸，服务于蛋白质组学、基因组学、生物制药生产、细胞生物学和食品安全市场。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Bio-Rad Laboratories</li>
<li>你应该将这些沃伦·巴菲特的股票加入你的投资组合吗？</li>
<li>3 只可购买的股票，底部坚实，准备反弹</li>
<li>10 月值得考虑购买的 3 只股票</li>
<li>Advantage+ 购物：Meta 快速增长的 200 亿美元 AI 广告明星</li>
<li>关于 Markup 计算器</li>
<li>Robotaxi 新闻：特斯拉和 Lyft 的头条对股票的影响</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJJTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJJTw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Bio-Rad Laboratories 吗？</h2>
<p>在你考虑 Bio-Rad Laboratories 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前...而 Bio-Rad Laboratories 并不在名单上。</p>
<p>虽然 Bio-Rad Laboratories 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

Bio-Rad实验室-A

<p>CIBC 私人财富集团有限公司在第四季度减少了对 Bio-Rad Laboratories, Inc.（纽约证券交易所代码：BIO）2.9% 的持股，目前持有 42,106 股，价值 1450 万美元。其他投资者，包括 Venturi Wealth Management 和 Picton Mahoney Asset Management，也调整了他们的持仓。分析师对该股票的评级不一，普遍评级为 “适度买入”，目标价为 395.20 美元。Bio-Rad 的股票开盘价为 244.29 美元，市值为 68.4 亿美元，报告每股收益为 2.90 美元，超出预期</p>

<p>CIBC Private Wealth Group LLC lowered its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 2.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 42,106 shares of the medical research company's stock after selling 1,243 shares during the quarter. CIBC Private Wealth Group LLC owned 0.15% of Bio-Rad Laboratories worth $14,500,000 as of its most recent filing with the Securities and Exchange Commission.</p>
<div class="lb-trans"><p>CIBC 私人财富集团有限公司在最近向证券交易委员会的披露中表示，在第四季度将其在 Bio-Rad Laboratories, Inc.（纽约证券交易所代码：BIO - 免费报告）的股份减少了 2.9%。该公司在本季度出售了 1,243 股后，持有 42,106 股该医疗研究公司的股票。根据其最近向证券交易委员会的备案，CIBC 私人财富集团有限公司持有 Bio-Rad Laboratories 的 0.15% 股份，价值 14,500,000 美元。</p>
</div><p>Get <strong>Bio-Rad Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Bio-Rad Laboratories</strong> 的提醒：</p>
</div><ul>
<li>S&amp;P 500 Shake-Up: New Entrants Driving Market Momentum</li>
</ul>
<div class="lb-trans"><ul>
<li>标普 500 震荡：新进入者推动市场动能</li>
</ul>
</div><p>Other large investors have also recently made changes to their positions in the company. Venturi Wealth Management LLC grew its position in shares of Bio-Rad Laboratories by 2,175.0% in the 4th quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company's stock valued at $30,000 after buying an additional 87 shares during the last quarter. Picton Mahoney Asset Management boosted its stake in shares of Bio-Rad Laboratories by 55.6% during the 4th quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company's stock worth $32,000 after acquiring an additional 35 shares in the last quarter. Asset Planning Inc acquired a new stake in Bio-Rad Laboratories in the 4th quarter valued at about $33,000. UMB Bank n.a. grew its holdings in Bio-Rad Laboratories by 41.6% during the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock valued at $36,000 after buying an additional 32 shares during the last quarter. Finally, Cape Investment Advisory Inc. purchased a new stake in shares of Bio-Rad Laboratories during the fourth quarter worth about $38,000. 65.24% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他大型投资者最近也对该公司的持仓进行了调整。Venturi 财富管理有限公司在第四季度将其在 Bio-Rad Laboratories 的股份增加了 2,175.0%。Venturi 财富管理有限公司现在拥有 91 股该医疗研究公司的股票，价值 30,000 美元，此前在上个季度又购买了 87 股。Picton Mahoney 资产管理在第四季度将其在 Bio-Rad Laboratories 的股份增加了 55.6%。Picton Mahoney 资产管理现在拥有 98 股该医疗研究公司的股票，价值 32,000 美元，此前在上个季度又收购了 35 股。Asset Planning Inc 在第四季度收购了 Bio-Rad Laboratories 的新股份，价值约 33,000 美元。UMB 银行在第四季度将其在 Bio-Rad Laboratories 的持股增加了 41.6%。UMB 银行现在拥有 109 股该医疗研究公司的股票，价值 36,000 美元，此前在上个季度又购买了 32 股。最后，Cape Investment Advisory Inc 在第四季度购买了 Bio-Rad Laboratories 的新股份，价值约 38,000 美元。目前，65.24% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级和降级</h2>
</div><p>A number of equities research analysts recently issued reports on the stock. Royal Bank of Canada restated an &#34;outperform&#34; rating and issued a $481.00 target price on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Wells Fargo &amp; Company dropped their target price on Bio-Rad Laboratories from $360.00 to $345.00 and set an &#34;equal weight&#34; rating on the stock in a report on Wednesday, February 12th. Finally, StockNews.com cut Bio-Rad Laboratories from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Monday, February 17th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $395.20.</p>
<div class="lb-trans"><p>一些股票研究分析师最近对该股票发布了报告。加拿大皇家银行在 1 月 14 日的报告中重申了 “跑赢大盘” 的评级，并对 Bio-Rad Laboratories 的股票设定了 481.00 美元的目标价。富国银行将 Bio-Rad Laboratories 的目标价从 360.00 美元下调至 345.00 美元，并在 2 月 12 日的报告中对该股票设定了 “持平” 的评级。最后，StockNews.com 在 2 月 17 日的报告中将 Bio-Rad Laboratories 的评级从 “买入” 下调至 “持有”。三位研究分析师对该股票给予了持有评级，三位分析师则给予了买入评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，共识目标价为 395.20 美元。</p>
</div><ul>
<li>The Top 3 Medical Devices Stocks to Buy Now</li>
</ul>
<div class="lb-trans"><ul>
<li>现在值得购买的前三大医疗设备股票</li>
</ul>
</div><p><strong>Read Our Latest Research Report on BIO</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 BIO 的最新研究报告</strong></p>
</div><h2>Bio-Rad Laboratories Stock Up 0.5 %</h2>
<div class="lb-trans"><h2>Bio-Rad Laboratories 股票上涨 0.5%</h2>
</div><p>Shares of NYSE BIO opened at $244.29 on Tuesday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48. Bio-Rad Laboratories, Inc. has a 1 year low of $235.84 and a 1 year high of $387.99. The stock's 50-day simple moving average is $291.56 and its 200-day simple moving average is $321.95. The firm has a market cap of $6.84 billion, a price-to-earnings ratio of -3.76 and a beta of 0.98.</p>
<div class="lb-trans"><p>纽约证券交易所 BIO 的股票在周二开盘价为 244.29 美元。该公司的债务与股本比率为 0.18，速动比率为 4.85，流动比率为 6.48。Bio-Rad Laboratories, Inc.的 1 年最低价为 235.84 美元，1 年最高价为 387.99 美元。该股票的 50 日简单移动平均线为 291.56 美元，200 日简单移动平均线为 321.95 美元。该公司的市值为 68.4 亿美元，市盈率为-3.76，贝塔值为 0.98。</p>
</div><p>Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. As a group, equities analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Bio-Rad Laboratories（纽约证券交易所代码：BIO - 获取免费报告）最后一次公布财报是在 2 月 13 日，医疗研究公司报告本季度每股收益（EPS）为 2.90 美元，超出分析师的共识预期 2.86 美元，超出幅度为 0.04 美元。Bio-Rad Laboratories 的股本回报率为 3.90%，净利润率为-71.86%。整体来看，股票分析师预计 Bio-Rad Laboratories, Inc.在当前财年将发布 10.81 美元的每股收益。</p>
</div><h2>About Bio-Rad Laboratories</h2>
<div class="lb-trans"><h2>关于 Bio-Rad Laboratories</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.</p>
<div class="lb-trans"><p>Bio-Rad Laboratories, Inc.在美国、欧洲、亚洲、加拿大和拉丁美洲制造和分销生命科学研究和临床诊断产品。它通过两个部门运营，分别是生命科学和临床诊断。该公司开发、制造和销售仪器、系统、试剂和耗材，以分离、纯化、表征和定量生物材料，如细胞、蛋白质和核酸，服务于蛋白质组学、基因组学、生物制药生产、细胞生物学和食品安全市场。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Bio-Rad Laboratories</li>
<li>Should You Add These Warren Buffett Stocks to Your Portfolio?</li>
<li>3 Buyable Stocks With Solid Bottoms Ready to Rebound</li>
<li>3 Stocks to Consider Buying in October</li>
<li>Advantage+ Shopping: Meta's Fast Growing $20 Billion AI-Ads Star</li>
<li>About the Markup Calculator</li>
<li>Robotaxi News: What Tesla and Lyft Headlines Mean for Shares</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Bio-Rad Laboratories</li>
<li>你应该将这些沃伦·巴菲特的股票加入你的投资组合吗？</li>
<li>3 只可购买的股票，底部坚实，准备反弹</li>
<li>10 月值得考虑购买的 3 只股票</li>
<li>Advantage+ 购物：Meta 快速增长的 200 亿美元 AI 广告明星</li>
<li>关于 Markup 计算器</li>
<li>Robotaxi 新闻：特斯拉和 Lyft 的头条对股票的影响</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJJTw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=BIO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bio-Rad Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Bio-Rad Laboratories 吗？</h2>
</div><p>Before you consider Bio-Rad Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Bio-Rad Laboratories 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Rad Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前...而 Bio-Rad Laboratories 并不在名单上。</p>
</div><p>While Bio-Rad Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Bio-Rad Laboratories 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

CIBC Private Wealth Group LLC 出售了 Bio-Rad Laboratories, Inc. (NYSE:BIO) 的股票